Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission.
Zidovudine monotherapy is used to reduce perinatal HIV transmission in women with low viral loads. There are few data on the risk of drug resistance in this select cohort of women. We determined the prevalence of newly acquired mutations conferring reduced sensitivity to zidovudine after exposure during pregnancy, and found that the development of mutations was uncommon and was restricted to women treated before 1998 who had higher baseline viral loads than those currently recommended monotherapy.
Larbalestier
Nick
N
Department of Genitourinary Medicine, Virology Section, Guys, Kings and St Thomas' School of Medicine, London, UK.
Mullen
Jane
J
O'Shea
Siobhan
S
Cottam
Fiona
F
Sabin
Caroline A
CA
Chrystie
Ian L
IL
Welch
Jan
J
Zuckerman
Mark
M
Hay
Phillip
P
Rice
Phillip
P
Taylor
Graham P
GP
de Ruiter
Annemiek
A
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D009154:Mutation / Q000235:genetics; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015215:Zidovudine; D054303:HIV Reverse Transcriptase